Biomarkers of HIV-1 associated dementia: proteomic investigation of sera.

ABSTRACT:

Background

New, more sensitive and specific biomarkers are needed to support other means of clinical diagnosis of neurodegenerative disorders. Proteomics technology is widely used in discovering new biomarkers. There are several difficulties with in-depth analysis of human plasma/serum, including that there is no one proteomic platform that can offer complete identification of differences in proteomic profiles. Another set of problems is associated with heterogeneity of human samples in addition intrinsic variability associated with every step of proteomic investigation. Validation is the very last step of proteomic investigation and it is very often difficult to validate potential biomarker with desired sensitivity and specificity. Even though it may be possible to validate a diff

SUBMITTER: Wiederin J 

PROVIDER: S-EPMC2666658 | biostudies-literature | 2009 Mar

REPOSITORIES: biostudies-literature